CCND1 and breast cancer: In BC patients, high tumor levels of SIRT6 were shown to enhance BC cell resistance to chemotherapeutics and to promote BC survival, migration, and invasion through the expression of cyclin D1, NF-κB, β-catenin, and matrix metalloproteinase 9 (MMP9) [16, 17].